GTC
SRPT icon

Ghost Tree Capital’s Sarepta Therapeutics SRPT Stock Holding History

Ghost Tree Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-200,000
Closed -$15.1M – 59
2019
Q3 		$15.1M Buy
+200,000
New +$23.6M 3.84% 8
2016
Q4 		– Sell
-400,000
Closed -$24.6M – 92
2016
Q3 		$24.6M Buy
400,000
+100,000
+33% +$3.02M 3.98% 4
2016
Q2 		$5.72M Buy
+300,000
New +$5.56M 1.65% 22

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ghost Tree Capital's SRPT Position: Q3 2024 in Review

Ghost Tree Capital increased its Sarepta Therapeutics (SRPT) stake by 118% in Q3 2024, buying an estimated $8.99M and bringing the position to 120,000 shares worth $15M. The position accounts for 4.53% of the portfolio, ranked #3.

Ghost Tree Capital first reported a position in SRPT in Q3 2015 and has held it in 26 quarters since. The position peaked at $44.1M in Q2 2019. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Ghost Tree Capital held 120,000 shares of Sarepta Therapeutics worth $15M as of Q3 2024.
  • Ghost Tree Capital bought 65,000 Sarepta Therapeutics shares in Q3 2024, an estimated $8.99M.
  • Sarepta Therapeutics made up 4.53% of Ghost Tree Capital's portfolio in Q3 2024, its #3 holding.
  • Ghost Tree Capital first reported a position in Sarepta Therapeutics in Q3 2015 and has held it in 26 quarters since.
  • Ghost Tree Capital's Sarepta Therapeutics position peaked at $44.1M in Q2 2019.
  • 457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.